https://www.selleckchem.com/pr....oducts/dir-cy7-dic18
5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. Age, APACHE II, SOFAvalue of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks. Administration of corticosteroids showed no benefits in mortality, as did treatment with tocilizumab. Lopinavir/ritonavir administration is identified as a protective factor. value of 6 points, along with vasopressor requirements or renal replacement therapy have been i